vascular targeting agent

Techniclone Issued Patent Extending Vascular Targeting Agent Portfolio

Techniclone Corporation was issued U.S. Patent No. 6,036,955 on March 14, 2000 entitled “Kits and Methods for the Specific Coagulation of Vasculature” by the U.S. Patent and Trademark Office. This patent covers particular methods of inducing molecules on tumour blood vessels for subsequent targeting and destruction and is a valuable addition to Techniclone’s existing broad Read more about Techniclone Issued Patent Extending Vascular Targeting Agent Portfolio[…]

duros leuprolide

Alza Exercises Option For Cancer Treatment

Crescendo Pharmaceuticals Corporation has announced that ALZA Corporation has exercised its option to obtain a worldwide license to DUROS leuprolide (Viadur), a once-yearly implant for the palliative treatment of advanced prostate cancer. DUROS leuprolide is the first product to provide continuous, 12-month testosterone suppression with a single treatment. Under the terms of its license agreement Read more about Alza Exercises Option For Cancer Treatment[…]

heska corporation

Heska Licenses Valentis Gene Delivery Technology

Heska Corporation has licensed gene delivery and DNA manufacturing technology from Valentis, Inc. The technology will be used by Heska to complete development of a novel gene medicine for the treatment of canine cancer. Specific terms of the agreement, which include an up-front license fee, milestone payments and a royalty, were not disclosed. Dr. Dan Read more about Heska Licenses Valentis Gene Delivery Technology[…]


Cell Therapeutics Receives FDA Approval For Trisenox

Cell Therapeutics, Inc. (cti) TRISENOX (arsenic trioxide) injection was approved today by the U.S. FDA to treat patients with a severe form of leukaemia whose disease has recurred or who have failed to respond to standard therapy. “For patients with APL whose disease has recurred following initial treatment, the use of salvage therapy is highly Read more about Cell Therapeutics Receives FDA Approval For Trisenox[…]

supergen inc

Supergen And Stehlin Foundation Expand Research Agreement

SuperGen Inc. has extended its research agreement with the Stehlin Foundation for Cancer Research to eight years. As part of this agreement, SuperGen also secured the global rights to other camptothecins and additional anticancer compounds. One of these compounds has already demonstrated marked antitumor activity and is expected to have a very favorable safety profile. Read more about Supergen And Stehlin Foundation Expand Research Agreement[…]


Amgen Receives EC Approval

Amgen has received EC approval for Aranesp and Neulasta as oncology therapies. The European Commission (EC) has approved both darbepoetin alfa (Aranesp/Nespo for the treatment of anaemia in adult cancer patients with solid tumours (non- haematological malignancies) receiving chemotherapy, and pegfilgrastim (Neulasta/Neupopeg) for the reduction in the duration of neutropenia and the incidence of febrile Read more about Amgen Receives EC Approval[…]

neoprobe corporation

Neoprobe Completes License For Lymphatic Agent

Neoprobe Corporation has announced that it has completed an exclusive license agreement with the University of California, San Diego (UCSD). The license affords Neoprobe the rights to a proprietary compound developed by researchers at UCSD. The compound, which Neoprobe has designated Lymphoseek (TM), is being evaluated in clinical studies to determine its effectiveness in identifying Read more about Neoprobe Completes License For Lymphatic Agent[…]

Centocor Expands Cancer Vaccine Agreement

Centocor, Inc., a Johnson & Johnson company, has expanded its earlier license and option agreement to use Vical‘s Incorporated naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer. Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future. The Read more about Centocor Expands Cancer Vaccine Agreement[…]

Isis, Lilly Expand Collaboration Into Cancer Drugs

Isis Pharmaceuticals Inc. and Eli Lilly and Co. have expanded their collaboration to develop cancer drugs based on a technology known as antisense. Isis, a small biotechnology company based in Carlsbad, California, and drug giant Lilly, based in Indianapolis, said they had formed a two-year collaboration to discover drugs associated with specific genes that the Read more about Isis, Lilly Expand Collaboration Into Cancer Drugs[…]